Antiviral therapies are notoriously difficult to develop, as viruses can quickly mutate to become resistant to drugs. But what if a new generation of antivirals ignores the fast-mutating proteins on the surface of viruses and instead disrupts their protective layers?
Neuro companies are one of pharma’s hottest M&A assets. But behind the scenes, there have been few bidders
Despite being a hot ticket in biopharma, neuroscience companies have attracted few bidders in the multibillion-dollar deals struck in recent months. An SEC filing Monday
January 23, 2024